Cataract Surgery in Uveitis by Agrawal, Rupesh et al.
Hindawi Publishing Corporation
International Journal of Inﬂammation
Volume 2012, Article ID 548453, 16 pages
doi:10.1155/2012/548453
Review Article
Cataract Surgery in Uveitis
Rupesh Agrawal,1 Somashiela Murthy,2 Sudha K. Ganesh,3 CheeSoon Phaik,4
Virender Sangwan,2 andJyotimaiBiswas3
1Tan Tock Seng Hospital, Singapore 308433
2L. V. Prasad Eye Institute, Andhra Pradesh, Hyderabad 500034, India
3Medical Research Foundation, 18 College Road, Tamil Nadu, Chennai 600006, India
4Uveitis and Cataract, Singapore National Eye Centre, Singapore 168751
Correspondence should be addressed to Rupesh Agrawal, rupesh agrawal@ttsh.com.sg
Received 21 September 2011; Accepted 28 October 2011
Academic Editor: Mark Willcox
Copyright © 2012 Rupesh Agrawal et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Cataract surgery in uveitic eyes is often challenging and can result in intraoperative and postoperative complications. Most
uveitic patients enjoy good vision despite potentially sight-threatening complications, including cataract development. In those
patients who develop cataracts, successful surgery stems from educated patient selection, careful surgical technique, and aggressive
preoperative and postoperative control of inﬂammation. With improved understanding of the disease processes, pre- and
perioperative control of inﬂammation, modern surgical techniques, availability of biocompatible intraocular lens material and
design,surgicalexperienceinperformingcomplicatedcataractsurgeries,andeﬃcientmanagementofpostoperativecomplications
have led to much better outcome. Preoperative factors include proper patient selection and counseling and preoperative control
of inﬂammation. Meticulous and careful cataract surgery in uveitic cataract is essential in optimizing the postoperative outcome.
Management of postoperative complications, especially inﬂammation and glaucoma, earlier rather than later, has also contributed
to improved outcomes. This manuscript is review of the existing literature and highlights the management pearls in tackling
complicated cataract based on medline search of literature and experience of the authors.
1.Introduction
One of the most daunting tasks for an ophthalmic surgeon is
the management of complicated cataracts. Cataract in uveitis
may develop as a result of the intraocular inﬂammation per
se, from chronic corticosteroid usage or more often from
both [1]. The incidence of cataract in uveitis varies from
57% in pars planitis [2] to 78% in Fuchs heterochromic
iridocyclitis (FHI) [3].
Cataract surgery in uveitic eyes is challenging and can
present with many unforeseen intraoperative complications.
Two decades ago, the outcome of surgery in these eyes was
guarded and often confounded by postoperative complica-
tionssuchassevereinﬂammation,hypotony,andevenphthi-
sis bulbi. However, with modern day cataract surgical tech-
niques,thisisseldomthecase.Withimprovedunderstanding
ofdiseaseprocesses,optimizationofimmunosuppressionfor
perioperative control of inﬂammation, minimally invasive
surgical techniques, availability of biocompatible intraocular
lens material and design and surgeons trained in performing
complicatedcataractsurgeriesandanticipatorymanagement
of postoperative complications [4], the outcome has been
maximized. Ocular morbidity in patients undergoing com-
plicated cataract surgery is now limited to those cases that
have pre-existing changes in the retina or optic nerve such
as irreversible macular scarring or optic nerve atrophy. The
fundamentals of cataract surgery in patients with diﬀerent
forms of uveitis have been recently reviewed by numerous
authors[1,4–17].Thispaperpresentsareviewoftheexisting
literature on this topic and proposes a set of management
pearlsintacklingcomplicatedcataractbasedontheliterature
review and authors’ combined experience.
Extensive literature search using OVID medline search
engine and all available library databases was employed with
references cross-matching to obtain all peer reviewed articles
published on cataract surgery in uveitis. The literature search2 International Journal of Inﬂammation
included all relevant published studies on cataract surgery in
uveitis since 1960 in English language.
2. HistoricalPerspective
Evolution of cataract surgery in uveitis. Until the advent
of corticosteroids in the early 1960s, ocular inﬂammation
was diﬃcult and often impossible to control, and articles
discussing the results of cataract extraction in inﬂamed eyes
reported a high incidence of severe complications [4, 6, 7,
10].
In many cases, the complications resulted in marked
reduction of vision or even loss of the eye [11]. More recent
publications have reported a considerable decrease in the
incidence of intraoperative and postoperative complications
during cataract extraction in uveitis [4–7, 12]. The most
l i k e l yr e a s o n sf o rt h i sv a s ti m p r o v e m e n tw o u l da p p e a rt ob e
the increased ability to control inﬂammation perioperatively
and the rapid evolution in microsurgical techniques that has
occurred in recent years.
3. Review of Current Literature
3.1. Cataract Extraction in Diﬀerent Uveitic Entities. Several
factors must be kept in mind when assessing the current
literature on cataract extraction in patients with uveitis.
Inﬂammatory squealae may develop at relatively predictable
rates in eyes with a given inﬂammatory syndrome [4–7, 11–
17]. However, these rates do vary markedly among syn-
dromes. It is therefore important to consider each syndrome
separately when assessing the results and complications
encountered following cataract extraction.
3.1.1. Cataract Surgery in Patients with Fuchs Heterochromic
Iridocyclitis (FHI). By far the largest volume of information
regarding cataract surgery in uveitis patients concerns those
with FHI. The uveitis tends to be low grade and chronic,
posterior synechiae rarely form, and patients are often
unaware of the disorder until complications develop or the
inﬂammationisdiscoveredduringaroutineeyeexamination
[18]. If patients are symptomatic, the two most common
symptoms at the time of presentation are blurred vision
as a result of cataract formation and vitreous ﬂoaters [18,
19]. The reported incidence of cataract formation in FHI
syndrome ranges from 15% to 75%, with the vast majority
of series reporting an incidence of around 50% [3, 4, 11, 13,
18, 19]. Most cataracts are of the posterior subcapsular type,
with the remainder being cortical or mixed [18].
Numerous studies of cataract extraction in FHI have
reported insigniﬁcant intraoperative and postoperative com-
plications. To summarize, the recurring complications seen
following cataract surgery in FHI, in order of reported
frequency, were hyphema, progressive vitreous opaciﬁcation,
glaucoma, and spontaneously resolving vitreous hemor-
rhage. Other complications such as retinal detachment,
extensive synechiae formation, and corneal edema were
reported by some authors [3, 18, 19].
The reported incidence of intraoperative and post-
operative hemorrhage varied from 3.6% to 76%. Recent
articles report a much lower incidence of hyphema than
was recorded previously, perhaps a result of the use of
improved microsurgical techniques. Javadi and colleagues
had safe outcomes with phacoemulsiﬁcation and in-the-
bag intraocular lens implantation in FHI, achieving a post
operativevisualacuityof20/40orbetterinall41eyesintheir
series. Vitreous haze was the major cause of postoperative
visual acuity of less than 20/20. In the follow-up period
of 17.8 ± 8.7 months, the only complication was PCO,
which developed in six (14.6%) eyes [18]. The most visually
signiﬁcant complication of cataract extraction in FHI eyes
appears to be the development of glaucoma. Permanent
elevation of IOP was reported to develop at some time
following the operation in 3% to 35% of these eyes [13].
The review of the literature reveals that, initially, control of
intraocular pressure can be achieved by medication alone,
but eventually up to 70% of these patients will require
ﬁltering surgery [13].
3.1.2. Cataract Surgery in Patients with Juvenile Idio-
pathic Arthritis (JIA). Not unlike inﬂammation associated
with FHI, the chronic nongranulomatous anterior seg-
ment inﬂammation associated with this condition is often
asymptomatic until complications supervene. However, the
complications arising from this syndrome are more severe.
The literature indicates that commonly encountered com-
plications include band keratopathy, extensive posterior
synechiae, and hypotony or glaucoma, in addition to
cataract.
Rehabilitation of 40–60% eyes with JIA that develop
cataract is considerably more diﬃcult than that in eyes with
FHI [20–31]. Numerous studies have reported the poor post
operative outcome of conventional cataract extraction even
without intraocular lens implantation. The largest series of
patients with JIA who had cataract extraction was reported
by Kanski and Shun-Shin [32]. Out of 162 eyes, 61 had
the cataract removed by needling and aspiration, and 101
had lensectomy and limited anterior vitrectomy. Vision was
hand motion or less in l5% of the lensectomized eyes,
20/400 to count ﬁngers in 30%, and better than 20/60 in
56%.
It was not until the important concept of adequate
immunosuppression aimed at zero tolerance of inﬂamma-
tion and abolishment of every cell was strongly advocated
and supported by clinical studies [22, 33] that patients
with JIA undergoing cataract surgery saw better visual
outcomes. In his landmark paper, Foster described the inten-
sive use of preoperative and postoperative corticosteroids
and reported visual acuities of 20/40 or better in 67%
of patients and no major intraoperative or postoperative
complications [22]. Subsequently several studies reported
successfulpostoperativeoutcomewithlimitedcomplications
with perioperative and postoperative immunosuppression.
Treatment with systemic, topical, and periocular steroids
is recommended during the perioperative period for all
eyes with uveitis associated with JIA that undergo cataractInternational Journal of Inﬂammation 3
extraction. Surgery should be delayed until the anterior
chamber is free of inﬂammatory cells (“ﬂare” will persist).
The addition of a limited vitrectomy in combination
with lens removal resulted in a decrease in the incidence of
phthisisfrom25%to2%inaseriesdescribedbyKanski[34].
Another similar study revealed the beneﬁcial outcome with
vitrectomy in patients with JIA-associated uveitic cataract
[35].
Successful use of intraocular lens implantation in uveitis
was reported by Probst and Holland in 1996 wherein visual
acuity of 20/40 or better was achieved in eight eyes at an
average follow-up period of 17.5 months; however the study
was limited by very small number of patients [26]. The
patients were operated at around a mean age of twelve years,
which was almost ﬁve years after the diagnosis of JIA in this
study as against the midteens in other studies.
A more recent study by Kotaniemi and Penttil¨ a in 2006
reported good postoperative outcome following intraocu-
lar lens implantation in patients with juvenile idiopathic
arthritis-associated uveitis where cataract surgery with
intraocular lens implantation was performed in 36 eyes and
the mean postoperative follow-up period was 3.3 years. The
visual result was good (>0.5) in 64%, moderate (0.3–0.5)
in 11%, and poor (0.3) in 25% eyes. Secondary cataract
developed in 16 eyes but in none of the eyes with primary
posterior capsulotomy and anterior vitrectomy. Secondary
glaucoma developed in 18 eyes, retinal detachment in 2 eyes,
cystoid macular edema in 16 eyes, and band keratopathy in
12 eyes [36].
Another major study published in 2009 by Qui˜ nones et
al. looking at cataract extraction in children with chronic
uveitis with 21 out of 34 children having JIA reported
good tolerance of intraocular lens in JIA patients and
good postoperative visual outcome with optimal control
of inﬂammation with immunomodulatory therapy. The
average followup reported in this study was more than four
years [33].
Recently published study by Ganesh and colleagues
analysed ten eyes of 7 patients who had phacoemulsiﬁcation
with IOL implantation done by a single surgeon. A heparin
surfacemodiﬁedIOLwasusedin7eyesandafoldableacrylic
IOL was used in 3 eyes. At ﬁnal followup, 70% of eyes had a
visual acuity of 20/40 or better and 30% had improved visual
acuityto20/60.Posteriorcapsularopaciﬁcationwasfoundin
2 eyes and anterior capsular ﬁbrosis in 1 eye [37].
Most JIA patients are in the amblyogenic age when they
develop cataracts and the surgeon must bear this in mind
when planning cataract surgery. For this reason, cataract
surgery cannot be withheld or delayed for too long whilst
battling to keep the eye quiescent in preparation for the
operation. Furthermore, primary capsulotomy with limited
anterior vitrectomy may be considered in children under the
age of six to eight years as performing YAG capsulotomy in
the postoperative period for posterior capsular opaciﬁcation
may be diﬃcult in a very young child.
A number of factors combine to make cataract surgery
more hazardous in these patients. These eyes have a marked
tendency to form synechiae [22]. Implantation of an IOL
into the capsular bag at the time of cataract removal often
results in reformation of posterior synechiae and develop-
ment of membranes over the IOL, resulting in cocooning
of the IOL [26]. This may results in malignant glaucoma
if the iris is plastered back onto the anterior capsule.
If seclusion or occlusion pupillae occur, secondary pupil
block glaucoma develops warranting a surgical peripheral
iridectomy[26].Withcycliticmembraneformation,traction
of the ciliary processes and ciliary body result in hypotony
and phthisis bulbi if surgery is not done early. Although
glaucoma is common in this syndrome due to the chronicity
of inﬂammation, with a reported incidence of about 25%
in most studies, some eyes are hypotonous by the time
cataract extraction is contemplated [22, 35]. In addition
to making surgery technically more diﬃcult, hypotony is
associated with an increased risk of postoperative choroidal
eﬀusion, macular edema, and phthisis. As a result of the high
risk of complications that may develop following surgery,
there is still controversy surrounding the implantation of
an IOL at the time of surgery [29]. These complications
are still very real despite the development of biocompatible
IOL materials. Thus, even with successful cataract surgery,
the outcome of cataract surgery in JIA patients is often
limited by the state of the optic nerve and the macula and
may be compromised by the presence of band keratopathy
[21, 22, 24].
3.1.3. Cataract Surgery in Patients with Intermediate Uveitis.
Inﬂammation in eyes with pars planitis is limited primarily
to the posterior segment, although mild anterior chamber
activity is present in some cases. This contrasts markedly
with the inﬂammation seen in Fuchs syndrome or JIA-
associated uveitis, which is located primarily anterior to the
lens. As the anterior chamber is largely free of inﬂammation
in intermediate uveitis, synechiae seldom develop and the
incidence of glaucoma is low [2]. As chronic inﬂammation
persists in close proximity to the lens, cataracts eventually
develop in 40% of patients [2]. Lens opacities ﬁrst develop
as a diﬀuse haze in the posterior subcapsular region. A large
percentage of the cataracts remain at this stage; only half of
the cataracts in one large series eventually became visually
signiﬁcant [2].
Macular edema is the major complication encountered
following surgery in pars planitis patients and is the most
important cause of poor vision. It has been seen to some
degree in almost half of the eyes that undergo cataract
extraction and is responsible for 80% of the eyes with less
than 20/40 vision. Generally, few other complications are
seen, and inﬂammation appears to remain under control
following surgery. The incidence of glaucoma after cataract
surgery in uveitis averages around 10%, which closely
parallels the natural rate of glaucoma in this syndrome [7].
Numerous studies have reported varying results of cataract
extraction in patients with intermediate uveitis [2, 4, 20,
38–42]. A possible reason for the varied outcomes is that
intermediate uveitis can take on a variable clinical course,
with approximately a third of all patients having a severe
prognosis despite therapy. There have been a few studies
which showed good postoperative outcome with vitrectomy4 International Journal of Inﬂammation
along with cataract extraction in patients with chronic
intermediate uveitis [43–47].
A large study by Ganesh and colleagues in 2004 [38]a n a -
lyzed the outcome of phacoemulsiﬁcation with intraocular
lens implantation in 100 eyes with intermediate uveitis. In
this study, 91% of eyes showed a favorable visual outcome at
average followup of 19.67 months. The major complications
reported by authors in this study were signiﬁcant posterior
capsular opaciﬁcation which occurred in 10%, CME in 50%,
reactivation of intermediate uveitis in 51%, IOL deposits in
29%,IOLdecentrationin1%,andanteriorcapsuleﬁbrosisin
14%. The three most frequent causes of poor visual recovery
were CME, submacular ﬁbrosis, and epiretinal membrane.
The authors concluded that phacoemulsiﬁcation with IOL
implantation in eyes with pars planitis was safe and led to
good visual outcomes in most cases. They attributed the
success to control of inﬂammation, meticulous surgery, in-
the-bag IOL implantation, and vigilant postoperative care.
3.1.4. Cataract Surgery in Behcet’s Disease. Cataract forma-
tion is the most common anterior segment complication
after recurrent inﬂammation, occurring in up to 36% of
cases [1]. It was reported that the postoperative visual acuity
was found to be signiﬁcantly lower in eyes with BD than in
those with idiopathic uveitis because of the severe posterior
segment complications, mainly optic atrophy [48].
Surgery is indicated whenever visual improvement can
be expected and the eye has been free of inﬂammation for a
minimum of 3 months. Operating on eyes with cataract and
uveitis has been previously reviewed by Foster and associates
[8]. Their recommendations for a successful cataract surgery
and for minimizing the postoperative uveitis are as follows.
Uveitis should be inactive for at least 3 months pre-
operatively, systemic and topical steroids should be used
prophylactically for 1 week preoperatively and continued
postoperatively, immunosuppressive drugs should be con-
tinued, complete removal of cortical material should take
place, and one-piece PMMA posterior chamber intraocular
lensshouldbeusedifthepatientandthesurgeonunderstand
the special nature of this surgery, its risks, and the prognosis
for success.
In another paper by Berker et al., the authors reported
results of phacoemulsiﬁcation and intraocular lens implan-
tation in patients with Behcet’s disease [49]. They reported
72.5% of eyes had improvement in vision after surgery.
However, the vision got worse in 17.5% of the eyes. Most
frequent complication reported by them was posterior
capsular opaciﬁcation in 37.5% of eyes. Other complications
were posterior seynchiae and severe inﬂammation. Posterior
segment complications such as epiretinal membrane forma-
tion, cystoid macular edema, and optic atrophy were also
reported by the authors.
3.1.5. Cataract Surgery in Patients with Idiopathic and Other
Forms of Uveitis. This group includes patients with uveitis
associated with sarcoidosis, toxoplasmosis, Vogt-Koyanagi-
Harada (VKH) syndrome, sympathetic ophthalmia, and
other types of uveitis. Duke-Elder [50] and Smith and
Nozik [51] both reported based on anecdotal evidence that
such patients do well following conventional surgery, as
long as inﬂammation has been absent for at least two to
three months preoperatively. Moorthy et al. [52]p e r f o r m e d
cataract surgery in 19 eyes of VKH. 68% of eyes had best
corrected visual acuity (BCVA) of >6/12. The most common
reason for BCVA <6/12 was pigmentary disturbance in
macula. In 1983, Reynard and Meckler [53] reported the
results of cataract extraction in six sympathizing eyes of
patients with sympathetic ophthalmia. All eyes showed min-
imal inﬂammation at the time of surgery, two eyes under-
went intracapsular cataract extraction, three extracapsular
cataract extraction, and in one case the cataract was needled.
Following surgery, all the eyes required steroid treatment
during followup to control recurrences of inﬂammation.
Uncontrolled inﬂammation led to the formation of cyclitic
membranes or phthisis in three eyes in spite of corticosteroid
therapy. Two eyes achieved visual acuity better than 20/40
during the follow-up period, which ranged from one to 23
years. The three eyes with severe postoperative inﬂammation
retained only light perception vision; one eye, with chronic
inﬂammation and macular edema, retained 20/100 vision.
Akova and Foster [54] analyzed results in 21 eyes of
sarcoidosis.61%eyesachievedastablevisualacuityof>6/12.
In2004 Ganesh et al. [55] reported results of cataractsurgery
in 59 eyes of VKH and found BCVA improvement by one
or more lines on Snellen’s chart in 40 (67.79%) eyes. PCO
w a ss e e ni n3 8( 7 6 % )e y e s ,f o l l o w e db yo p t i ca t r o p h ya n d
subretinal gliosis.
Fox et al. [23] described 16 patients with various types
of uveitis associated with ankylosing spondylitis in 5 and
inﬂammatory bowel disease in two. All patients had less
than 0–2 anterior chamber cells for at least three months
preceding surgery. Cataracts were removed by extracapsular
techniques, including phacoemulsiﬁcation, and 14/16 eyes
had posterior chamber intraocular lenses implanted. Vision
improved in all cases, with most eyes achieving 20/40 or
better visual acuity. Few complications were noted, the
most serious appeared to be the development of posterior
synechiae and in 6/14 eyes (43%), macular pathology was
seen postoperatively.
4. CurrentGuidelinesfor the Management of
Uveitic Cataract
4.1. Clinical Evaluation of Complicated Cataract and Asso-
ciated Uveitis. The eye in which visual loss is mainly
attributable to cataract formation is most likely to beneﬁt
from cataract surgery. The outcome of surgery depends
upon several factors, namely the uveitic diagnosis, proper
perioperative management and meticulous surgery. The
speciﬁc uveitic diagnosis is of paramount importance also
when planning the surgical strategy [4], such as determining
whether an intraocular lens should be implanted or not.
Diseases that spare the posterior segment generally have
a better prognosis than those that aﬀect the macular and/or
optic nerve. Acute uveitic syndromes tend to be associated
withbetteroutcomesthanchronicuveitis.Thus,JIApatients,International Journal of Inﬂammation 5
(a) (b)
Figure 1:A54-year-oldfarmergavehistoryoflossofvisionandrepeatedepisodesofrednessandpaininthelefteyefollowinginjury40years
ago. B scan of the left eye showed ﬁndings suggestive of old vitreous hemorrhage and retinal detachment. Since visual acuity was doubtful
perception of light, surgery was not advised for him. Diﬀuse (a) and slit (b) photographs show the left eye with peripheral corneal scar and
peripheral anterior synechiae and total posterior synechia with cataract. At the temporal periphery, there is an incidental conjunctival lesion
suggestive of actinic keratosis. Note the polychromatic crystals (cholesterolosis) deposited on the iris.
especially those with anterior uveitis in the pediatric age
group [56] have more poor outcome than patients with
ankylosing spondylitis and anterior uveitis.
The visual potential of the eye, determined by prior per-
manent structure damage, should be carefully determined
before planning cataract surgery as this will have a direct
impact on the visual outcome. The state of the macula
and optic nerve should be thoroughly examined for during
the preoperative assessment. Macular ischemia, atrophy,
chronic macular edema, or scar, such as that resulting from
a choroidal neovascular membrane, are poor prognostic
factors. Similarly, optic atrophy and severe cupping of
the optic disc are bad prognostic signs. Furthermore, the
state of the retina must also be carefully examined for
evidence of ischemia. In presence of dense lens opacity, B
scan ultrasonography should be done to rule out retinal
detachment which may complicate the eye with uveitis. In
eyes with chronic retinal complications, possibly the cataract
surgery may not result in optimal and desirable visual
outcome and such cases are left to the discretion of surgeon
to operate under nil visual prognosis or for cosmetic reasons
(Figures 1(a) and 1(b)). Less disabling abnormalities such as
pre-existing corneal scars and severe iris atrophy may also
compromise the visual outcome.
Regardlessoftheguardedprognosis, adeﬁniteindication
for cataract removal in an eye that is not blind, is phacoanti-
genic uveitis. This may result from the hypermature state
of a cataract, whereby lens proteins leak out of the capsular
bag through an intact capsule, or in cases of trauma, where
the lens capsule has been breached, leading to persistence
of intraocular inﬂammation. Cataract surgery may also be
indicated to permit better visualization of the posterior
segment for appropriate medical or surgical management of
the eye [57].
4.2. Control of Pre Operative Inﬂammation. The risk of
reactivation of uveitis must be assessed. Jancevski and Foster
recommended the use of supplementary perioperative anti-
inﬂammatorytherapytopreventdamagetoocularstructures
essential to good vision [58]. This has been shown to
reduce the risk of postoperative CME [59]. In eyes which
are at risk of developing macular edema postoperatively,
such as chronic anterior uveitis secondary to sarcoidosis;
or eyes with previous episodes of CME (e.g., intermediate
uveitis), steroid prophylaxis should be given perioperatively
to protect against recurrence of macular swelling. Similarly,
steroid prophylaxis should be administered in eyes at risk of
developing recurrence of uveitis following cataract surgery,
for example, Vogt-Koyanagi Harada disease, Behcet’s disease
and birdshot choroidopathy, to name a few. This may take
the form of oral steroids 1mg per kg/day starting 3 days
preoperatively, tapering the steroid dose according to the
amount of inﬂammation postoperatively. Generally, the oral
steroids are tapered or reduced to the preoperative levels
over the subsequent month, whilst maintaining the dose of
other concurrent immunosuppressive therapy. Alternatively,
if there are no contraindications to periocular steroid
injections,suchasdocumentedsteroidresponseorinfectious
uveitis, an orbital ﬂoor or sub-tenon’s injection of depot
steroid, such as triamcinolone acetonide 40mg/1mL may
be given, especially in patients where high doses of oral
steroid are contraindicated, for example in poorly controlled
diabetics. In addition, guttae prednisolone acetate 1% 2
hourly administered 2 days prior to surgery, together with
an oral and topical non-steroidal anti-inﬂammatory agent,
can be given. Supported by encouraging results in the recent
literature, the authors favour an intravitreal injection of
preservative-free triamcinolone acetonide 4mg in 0.1mL at
the conclusion of cataract surgery [60–62]. This has been
shown to be as eﬀective as prescribing systemic steroids
perioperatively. Similarly, optimal control of periocular
inﬂammation is imperative in cases with sclerokeratouveitis
for optimal surgical and visual outcome (Figures 2(a) and
2(b)). In eyes with types of infectious uveitis that have
a propensity to recur, such as ocular toxoplasmosis and
herpes simplex uveitis, preoperative prophylaxis should also
be considered as surgery may trigger reactivation of the
infection. Toxoplasmic retinochoroiditis is associated with
a 36% risk of reactivation following surgery [63]. Herpes6 International Journal of Inﬂammation
(a) (b)
Figure 2: A 48-year-old lady was diagnosed as bilateral sclera-keratouveitis, with complicated cataract. She was investigated extensively
and had a positive Mantoux test, for which she received anti-tubercular therapy. She underwent cataract surgery in the left eye with a
preoperative visual acuity of counting ﬁngers. Postoperatively, her visual acuity improved to 20/125, limited by the presence of a central
corneal scar. (a) Shows the right eye showing evidence of healed scleritis, corectopia, and a complicated cataract. (b) Shows the left eye two
months postoperatively.
simplex is also associated with reactivation following the
stress of surgery, and acyclovir 400mg bid or valtrex 0.5gqd
preoperatively and for 2 to 3 weeks postoperatively may
help prevent recurrence. In addition, topical NSAID and
prednisolone acetate 1% or even oral NSAID may help
control postoperative inﬂammation [64].
4.3. Complications of Uveitis Adversely Aﬀecting Surgical
Outcome:High-RiskSurgicalCases. Determiningthesurgical
risk is a very important aspect of preoperative assessment.
Eyes which have generally low intraocular pressures, espe-
cially readings of 6mmHg or less even when quiescent, are
at high risk of developing postoperative hypotony or even
phthisis bulbi. Other warning signs such as seclusio papillae
with normal intraocular pressure reading and apparent
phacodonesis without evident zonulysis are important poor
prognostic signs for postoperative hypotony. Eyes in which
t h eu v e i t i si sd i ﬃcult to control are also at high risk of severe
postoperative inﬂammation and hypotony or phthisis bulbi.
T h ep r e s e n c eo fc h o r o i d a le ﬀu s i o no nBs c a nu l t r a s o n o g r a -
phy or diﬀusely thickened choroid is a poor prognostic sign.
Conducting a careful ultrasonic biomicroscopy is essential
in eyes with relative hypotony [65] to assess the state of
the ciliary body and its processes. If the ciliary body has
undergone atrophy, the risk of hypotony is high. If the ciliary
body is found to be detached and processes appear under
traction from a ciliary (cyclitic) membrane, cataract surgery
should be combined with vitrectomy and trimming of the
ciliary membrane aided by indentation of sclera to relieve
ciliary body traction and to restore normal IOP.
4.4. Diagnostic Aids. Apart from the standard means of
assessing macular, optic nerve and retinal function, one may
apply additional methods such as pupillary response, light
projection, colour perception and B scan ultrasonography,
oranattemptedOCTinlookingformacularatrophy,edema,
or hole [66]. Performing a macular potential test using laser
interferometry may help in determining minimum visual
potential [67]. A fundus ﬂuorescein angiogram may also
demonstrate macular ischemia or edema, retinal ischemia,
active posterior segment disease, including disc leakage [68].
Considering the risk of post operative hypotony and to
rule out cyclitic membrane preoperatively in chronic uveitic
cases with bound pupils as described above, ultrasound
biomicroscopy can also aid preoperative surgical planning
[65]. Finally, the laser ﬂare meter is a useful tool to measure
ﬂare in the anterior chamber and may be used to determine
if the eye is quiet. It also helps guide therapy as it can be used
tomonitorthelevelofinﬂammationintheanteriorchamber
during the postoperative period [69].
4.5. Optimal Time for Cataract Surgery. Before scheduling
surgery, the ophthalmologist should attempt to ensure that
the eye has been quiescent for at least 3 months [11]. This
has been shown to reduce the risk of postoperative CME
[59]. In cases where, despite heavy immunosuppression, the
intraocular inﬂammation is still not completely abolished
and surgery is urgently required, such as in an intumes-
cent cataract, the patient may be administered intravenous
methylprednisolone 1g one day before surgery. A study from
Japan suggests that in patients with Behcet’s disease the eye
should be inactive for a minimum of 6 months and that the
risk is higher if attacks have occurred within 12 months of
cataract surgery [70].
4.6. Counselling of the Patient for Uveitic Cataract Surgery.
The most important aspect of counselling when planning
to perform cataract surgery for the uveitic eye is explaining
the visual prognosis. The general risks involved in surgery,
such as infection and other intraoperative complications
will also need to be thoroughly explained, especially if
there is phacodonesis, hypotony, or glaucoma. Emphasizing
that the eye will need a minimum period of quiescence
before surgery to minimise the chance of recurrence and
improve the visual outcome is important. Furthermore, it
is important to explain that surgery may be complicated
and possibly take longer than usual because of abnormal
anatomy, such as the presence of synechiae, membranes,International Journal of Inﬂammation 7
and so forth, and that these factors may contribute to
postoperative inﬂammation. Other factors requiring careful
discussion and explanation include the possibility of and
reasons for delayed visual recovery, the need for compliance
with medications (systemic immunosuppression may need
to be adjusted), and frequent followup, especially if the
patient has diﬃculty accessing medical care.
These patients are often young, therefore losing a lens
that was still able to accommodate in exchange for an
intraocular lens implant means loss of accommodation.
Consequently, they will need to understand and accept the
fact that they will now need reading glasses. The type of IOL
implant, the material, and design are all important points
that need discussion. The choice of intraocular lens can be
based on the extensive literature available [39, 71–74].
Generally,multifocalimplants,whetherbasedondiﬀrac-
tive or refractive principles may compromise the visual
outcomes due to the presence of preexisting macular or optic
nerve conditions. Hazy or scarred vitreous gel contributes
to poor contrast sensitivity and any previous episode of
inﬂammation with macular involvement increases the risk
of poor visual performance with multifocal implants. These
patients do better with a monofocal IOL implant. Even
accommodative IOLs may not be eﬀective in the long term
due to recurrent inﬂammation and scarring of the ciliary
body, or slowly progressive ﬁbrosis of the capsular bag.
Posterior capsule opaciﬁcation is another frequent com-
plication encountered postoperatively because of the relative
youth of these patients [75]. Choice of IOL, as will be
discussed later (see IOL implantation-contraindications and
type of IOL), and surgical technique are major determining
factors as well. Occasionally, opacities are observed during
the surgery, and some surgeons prefer to perform a primary
posterior capsulorhexis at the time of the cataract surgery
before implanting the IOL [76]. This possibility should be
discussed with the patient before surgery, especially in view
oftheincreasedrisk ofpostoperative endophthalmitis, CME,
and retinal detachment.
Should the patient have complications other than
cataract formation alone, the option of separate, staged, or
combined surgery should be discussed with the patient and
advice given regarding their risks and beneﬁts [77].
5.SurgicalTechnique
5.1. Choice of Surgery. T h ec h o i c eo fc a t a r a c ts u r g e r yt e c h -
nique is best left to the surgeon and depends upon the
individual surgeon’s surgical skill and experience. Cataract
removal by phacoemulsiﬁcation is safer for the uveitic
cataract as less inﬂammation is induced than that by a man-
ual extracapsular cataract extraction. During the surgery, the
anatomy of the anterior segment should be restored to a state
a sc l o s et on o r m a la sp o s s i b l e .
Some uveitic cataract eyes are complicated by glaucoma
or retinal problems that may also beneﬁt from surgery.
For eyes with concomitant uveitic glaucoma, surgery is
preferably not combined with the cataract surgery as the
risk of bleb failure is increased with drainage of post-
cataract surgery inﬂammatory exudate through a healing
bleb. Where possible, cataract surgery should be done ﬁrst.
Regarding retinal complications, such as epiretinal mem-
branes or coexisting retinal detachment, cataract surgery
may be combined with vitreoretinal surgery. In cases with
major retinal problems, the eye may be safely rendered
aphakic until the retinal problem has been dealt with. In
eyes with intermediate uveitis, or FHI, cataract surgery
may be combined with vitrectomy, performed to clear
the vitreous gel, thereby reducing vitreous clouding. In
intermediate uveitis, this often not only improves vision but
also controls intraocular inﬂammation and helps resolve the
cystoid macular edema. At the end of surgery, especially
with combined surgical procedures, having excluded steroid
responders and eyes with infectious uveitis, an intravitreal
injection of triamcinolone acetonide, is often adequate to
control the postoperative inﬂammation and prevent CME.
The risks and beneﬁts of combining or separating the
surgical procedures should be thoroughly explained to the
patient.
5.2. Intraoperative Surgical Techniques and Skills [78]
(a) Posture. Patients with ankylosing spondylitis with a ﬁxed
ﬂexion deformity of the axial spine, especially when the
cervical spine is involved, have diﬃculty not only in placing
their chin on the slit-lamp rest but also lying ﬂat on the
operating table for ocular surgery. These patients are best
postured in the Trendelenburg position, whereby their lower
limbs are elevated above the level of their head, so as to
maintain theplaneofthefaceparalleltotheﬂoor.Thepillow
support may need to be stacked up high in order to support
the head. As the patient tends to slide down the bed, a strap
is best secured around the torso to prevent the body from
slipping.
(b) Surgical Challenges. The uveitic eye poses numerous
surgical challenges. These include the small pupil, shallow
anterior chamber, posterior synechiae, peripheral ante-
rior synechiae, pupillary membranes and even zonulolysis.
Complications that may arise from the problems include
an undersized or incomplete capsulorhexis, iris prolapse,
increased risk of posterior capsular rent, increased risk of
intraoperative zonular dehiscence, and increased postoper-
ative inﬂammation.
(c) Anaesthesia. Whilst phacoemulsiﬁcation surgery may be
done under topical anesthesia, manipulation of the iris may
induce ocular discomfort or pain. Either regional anesthesia
or an intracameral injection of preservative-free lignocaine
1% can provide adequate analgesia. For children and in
patients for whom prolonged surgical time is anticipated,
as in severe zonulolysis requiring modiﬁed capsular tension
ringsthatneedsuturing,generalanesthesiamaybepreferred.
(d) Incision. Either a scleral or temporal clear corneal
incision may be used. However, the incision should be of8 International Journal of Inﬂammation
(a) (b)
Figure 3: (a) Showing the eye with synechiae at papillary border, pigment deposition on the lens, and an early cataract and (b) showing
presence of 360 degree posterior synechiae.
(a) (b)
Figure 4: Intraoperative use of Kuglen hooks to stretch and dilate the pupils.
Figure 5: Postoperative slit lamp photograph showing minimally
distorted pupil following pupil manipulation intraoperatively to
negotiate posterior synechiae.
adequate length in order to prevent iris prolapse in eyes with
small or stretched pupils.
(e) Pupil Enlargement. An attempt at pupil dilation can be
made by injecting balanced salt solution with adrenaline
(1:1000 0.5mL adrenaline in 500mL) into eyes with pupils
thatarenotboundbysynechiaeormembranes.Preservative-
free intracameral lignocaine 1% may also be used to help
dilatethepupilonlyifitisnotbound.Choosingaviscoadap-
tive viscoelastic such as Healon 5 (sodium hyaluronate 2.3%,
Abbott Medical Optics) is useful as this high-molecular-
weight sodium hyaluronate can physicallyroll open the pupil
and keep it dilated as long as the aspiration ﬂow rate is kept
low.
(f) Synechiolysis and Removal of Pupillary Membrane.
Synechiae may be present between the iris and the anterior
lens capsule (posterior synechiae, PS) (Figures 3(a) and
3(b)) or may form between the peripheral iris and corneal
endothelium as a result of previous iris bombe (peripheral
anterior synechiae, PAS). When both are present, the PAS
should be released before the PS. Release of PAS may be done
by injecting viscoelastic, such as Healon 5 (Viscoadaptive
from Abbott Medical Optics, Inc. Abbott Park, Ill, USA), to
physically separate the iris from the cornea, failing which the
tip of the viscoelastic cannula may be used to sweep the iris
away from the peripheral cornea as the viscoelastic material
is being injected into the angle of the anterior chamber. This
should be done very gently and carefully, taking care not
to detach Descemet’s membrane in the process. PS may be
lysed by simply injecting viscoelastic against the adherent
iris, allowing the viscoelastic to “bulldoze” the iris away
from the anterior capsule. Alternatively, this may be done byInternational Journal of Inﬂammation 9
(a) (b)
(c)
Figure 6: Intraoperative use of self-retaining iris hooks to dilate the pupils.
(a) (b)
(c)
Figure 7: Postoperatively removal of self-retaining iris hooks.10 International Journal of Inﬂammation
Figure 8: Intraoperative still video clip demonstrating the step of
capsulorrhexis.
sweeping the pupil free from the lens capsule with a cannula.
In cases where a narrow strip of membrane is present at
the site of PS formation, a 27-gauge needle may be used to
simultaneously nick the membrane to segment and release it
from the anterior capsule and release the PS, thus stretching
the pupil.
(g) Pupil Expansion. The most user-friendly instrument
for extensive synechiae once an edge of the iris has been
viscodissected oﬀ the anterior capsule is a bent Kuglen hook.
This“push-pull”instrumentisexcellentforthesafereleaseof
PS, ranging from mild to extensive, as it enables the surgeon
to push or pull the iris, thereby releasing the iris from the
anterior lens capsule, even when a pupillary membrane is
present. When the pupil has been freed, the membrane
can be removed using a pair Kelman-Mcpherson forceps.
Often, once the pupillary membrane has been removed, the
pupil begins to widen with viscoelastic. However, if this is
inadequate, the pupil may be stretched using a pair of angled
Kuglen hooks introduced through the main incision, used in
a manner to latch around the pupil edge, pulling the iris in
opposite directions (Figure 4(a)). This is then repeated in a
direction perpendicular to the initial stretch (Figure 4(b)).
The surgeon should stop at once should the iris sphincter
develop a tear. If proper execution of pupil manoeuvring
is done, postoperatively pupil looks relatively round with
minimal distortion of pupillary margins (Figure 5). The
pupil may then be further enlarged using multiple sphinc-
terotomies by means of intraocular scissors, taking care not
to compromise the anterior capsule.
Alternative means of opening the pupil include the use
of a Beehler pupil dilator (2 or 3 pronged) to mechanically
stretch the pupil in a single injector system. Pupil retainers
may also be tried. Disposable iris hooks are easy to place
through multiple corneal paracentesis (Figures 6(a)–6(c)).
The iris hooks are removed at end of surgery (Figures 7(a)–
7(c))). More recently a pupil device, the Malyugin ring
(Microsurgical Technologies, Redmond, Wash, USA) has
been used, which may be injected into the anterior chamber
through a 2.2mm incision and manoeuvred to expand and
maintain the pupil open at a 6 or 7mm diameter.
(h) Continuous Circular Capsulorhexis. It is generally prefer-
ableto keep the size of thecapsulorhexis slightly smallerthan
the pupil so that iris chaﬃng does not occur and results
in progressive intraoperative miosis as nuclear fragments
are being moved out of the capsular bag (Figure 8). This
also contributes to increased postoperative inﬂammation.
When the pupil size is small, the capsulorhexis inevitably
needs to be larger than the pupil. The anterior chamber
must be kept deep and the anterior capsule ﬂattened using
adequate viscoelastic material in order to control the tearing
of a capsulorhexis. The capsulotomy can be initiated by a
26- or 27-gauge bent cystitome and a modiﬁed vitreoretinal
forceps (pediatric rhexis forceps) can be then inserted from
the side port to complete the rhexis. Creating the ideal
capsulorhexis is also very important in preventing posterior
capsule opaciﬁcation. The capsulorhexis should be centred,
overlappingtheedgeoftheopticatalltimes,butnotsosmall
as to prevent capsular phimosis.
(i) Nucleus Management. In small pupils, the safest tech-
nique is the vertical chop employed in the in situ chop
technique. Chopping of fragments is done within the
pupillary aperture with the phaco tip kept in view at all
times with minimal risk of engaging and traumatizing the
iris (Figures 9(a) and 9(b)).
(j) Irrigation and Aspiration. This step must be done thor-
oughly so as not to leave cortical material behind. The eye
shouldberotatedtolookforresiduallensmatterandagentle
shake given at the end of nucleus removal to ensure that no
fragments are still lodged in the posterior chamber during
phaco (Figure 10).
(k) Intraocular Lens Implantation Contraindications and Type
of IOL. The review of the literature suggests that while
earlier, implantation of IOLs in uveitic eyes with JIA and
chronic uveitis was considered a contraindication, now with
modernIOLs,itmaybesafetoimplantIOLsinthesediﬃcult
casescenariosaslongastheuveitisiswellundercontrol.Ali´ o
et al. [39, 79] showed that the most biocompatible IOL for
the anterior chamber and the capsular bag is a single-piece,
square-edged acrylic (either hydrophilic or hydrophobic)
IOL. They also found that the posterior capsular opaci-
ﬁcation rate was highest (34.2%) in eyes with silicone
IOLs. In addition, silicone IOLs had a higher incidence of
postoperative cystoid macular edema and PS formation, and
pupillary membranes were formed only in eyes with silicone
IOLs. In general, hydrophilic acrylic material has good uveal
butworsecapsularbiocompatibility, buthydrophobicacrylic
materialhadloweruvealbutbettercapsularbiocompatibility
[78]. In eyes with chronic uncontrolled uveitis, IOL implant
should be deferred.
R e m o v a lo fv i s c o e l a s t i cf r o mu n d e rt h eI O Li sa n
important step in reducing the space behind the IOL into
which lens epithelial cells tend to migrate, thus causing PCO.
Pressing the optic against the posterior capsule when using a
single-piecehydrophobicIOLalsoencouragesitsadhesionto
the posterior capsule, thereby reducing the risk of PCO [79].International Journal of Inﬂammation 11
(a) (b)
(c)
Figure 9: Intraoperative still surgical video clip showing the nucleus management in total white uveitic cataract.
Figure 10:Intraoperativestillsurgicalvideoclipshowingirrigation
and aspiration of the soft lens matter.
5.3. Complications and Postoperative Management
5.3.1. Intraoperative Complications
Zonulolysis. An infrequent intraoperative complication is
Zonulolysis. This can occur in eyes with chronic uveitis.
Insertion of a plain capsular tension ring (CTR) is often
necessary in order to prevent IOL decentration. However,
if the overall zonular strength is weak, ﬁxation of the CTR
to the sclera by means of a modiﬁed Cionni CTR ensures
that the IOL remains centred. Failure to use a CTR in the
presence of weak zonules may result in capsular phimosis,
due to unopposed capsular bag ﬁbrosis and shrinkage.
Retained Lens or Nuclear Fragments. Due to the small pupil
size, small hard nuclear fragments may lodge in the posterior
chamber during phacoemulsiﬁcation, only to pop into the
anterior chamber months later. These small fragments can
cause recurrent anterior uveitis when their position in the
anterior chamber changes and may also cause localized
corneal edema and even localized corneal decompensation
in the long term. Hence, at the end of phaco, the eye
should be given a gentle shake whilst aspirating to ensure no
nuclear fragments are inadvertently left behind. Any retained
soft lens material or nuclear fragment should be removed
surgically as soon as possible [80].
5.3.2. Early Postoperative Complications
Excessive Postoperative Inﬂammation. One of the most com-
mon postoperative complications is excessive postoperative
inﬂammation (Figures 11(a)–11(g)) .T h i sm a yv a r yi nt e r m s
of severity or duration of inﬂammation. Associated with this
is the development of cystoid macular edema, which may
be treated by controlling the inﬂammation. The incidence
of CME following extracapsular cataract surgery in uveitic
eyes is frequent and has been reported to range from
33% to 56% [10, 14]. Following phacoemulsiﬁcation, the
incidence has been reported to range from 12% to 59% [38].
Generally, if preoperative prophylactic oral steroids have
been given and maximal topical steroids and cycloplegics
have proven ineﬀective in controlling the uveitis, the dose12 International Journal of Inﬂammation
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(c) (d)
(e) (f)
(g) (h)
Figure 11: A 45-year-old man, a treated case of Hansen’s disease 15 years ago, presented with progressive visual loss. Examination showed
active anterior uveitis and complicated cataract. He was treated with topical steroids and after 4 months, underwent phacoemulsiﬁcation
with PCIOL in the left eye. On the ﬁrst postoperative day, his visual acuity improved to 20/50 (from preoperative vision of 20/200) with a
mild ﬁbrinous reaction in the anterior chamber. He returned to the emergency clinic on the next day with loss of vision and showed severe
anterior chamber reaction with hypopyon. Vitreous appeared uninvolved. He was hospitalized and treated with intensive topical steroids
and cycloplegics. He improved over the course of one week and regained good vision at the end of one month. (a, b) show the right and
left eye with quiet anterior chambers and nondilating pupil with posterior synechia. (c, d) Diﬀuse and slit view of the left eye on the second
postoperative day shows hypopyon and coagulum around the IOL. (e, f, g) Diﬀuse low and high magniﬁcation and slit view of the left eye
two days after intensive treatment showing decrease in the inﬂammation. (h) The left eye shows near-quiet anterior chamber 2 weeks after
treatment, the visual acuity has improved to 20/50.International Journal of Inﬂammation 13
(a) (b)
Figure 12: A 36-year-old man presented with a history of redness and pain since two years and decreased vision since one year. Examination
showed a total cataract in the right eye, with 360 degrees posterior synechiae. Investigations showed HLA-B 27 was positive. After the
inﬂammation subsided, the patient underwent cataract surgery with synechiolysis. Postoperatively, there was increased anterior chamber
inﬂammation, which was treated with oral and topical steroids. The patient regained visual acuity of 20/25; 3 months postoperatively and is
on maintenance with oral methotrexate and topical steroids. (a, b) Diﬀuse and slit photograph of the right eye on the ﬁrst postoperative day
shows a membrane on the IOL which responded to intensive topical steroids and cycloplegics.
of oral steroids may be sharply increased. If no prophylactic
oral steroids had been given the patient should be given an
oral pulse of steroids or injection of periocular steroids. An
alternative means would be to give an intravitreal injection
of triamcinolone acetonide [81]i ft h i sh a dn o tb e e ng i v e n
intraoperatively, thus avoiding the need to adjust the sys-
temic immunosuppression. In the pediatric eye with chronic
uveitisundergoingcataractsurgery,amultistagesurgerymay
be the safer approach, whereby various complications are
addressed at diﬀerent sittings [79]. This strategy may avoid
postoperative complications and improve surgical outcomes.
Posterior synechiae, pupillary or ciliary membrane for-
mation may occur during the postoperative period due to
excessive inﬂammation (Figures 12(a) and 12(b)). Control
of uveitis and keeping the pupil mobile during this time are
important.
Intraocular Pressure (IOP) Abnormalities. The IOP may be
raised transiently during the early postoperative period in
eyes with compromised trabecular meshwork or angles.
This can often be managed with topical and systemic anti-
glaucoma medications.
However, the surgeon’s greatest fear is hypotony. Once
wound leakagehasbeen ruled out, the next step is to increase
the anti-inﬂammatory therapy topically and systemically.
This is often eﬀective in raising the IOP, but the topical
steroids may be diﬃcult to taper or withdraw and patients
may require long-term topical steroids to maintain the IOP.
Stabilisation of the IOP and vision has been successfully
treated with an intraocular injection of sodium hyaluronate
v i aal i m b a lp a r a c e n t e s i si nn o nu v e i t i ce y e s[ 82]. In severe
cases, vitrectomy and trimming of ciliary body traction
membranes and silicone oil ﬁlling may be needed if UBM
shows the presence of ciliary body detachment secondary
to tractional membranes not addressed during the cataract
surgery [83].
Recurrence of Uveitis. Increased frequency of recurrence
following cataract surgery may occur. This is thought to
be triggered by the intraocular procedure. The recurrence
r a t eh a sb e e nr e p o r t e dt ob ea sh i g ha s5 1 %[ 15]. Hence,
stepping up the immunosuppression for the long term may
be necessary to prevent further recurrences.
5.3.3. Late Postoperative Complications
Posterior Capsular Opaciﬁcation. In the late postoperative
period, posterior capsular opaciﬁcation is perhaps the
most common complication following any type of cataract
surgery. Okhravi et al. [9] reported an incidence of 48.0%,
Rauz et al. [84] 81.7% and K¨ uc ¸¨ ukerd¨ onmez et al. [82] 34.2%
at 1 year. Their corresponding Nd:YAG capsulotomy rates
were 32.2%, 8.3%, and 3.6%.
Preventive measures include creating a circular well-
centred capsulorhexis which is smaller than the optic size,
using an acrylic IOL with a square-edged optic design,
meticulous removal of viscoelastic from within the capsular
bag and ensuring the optic is stuck on to the posterior
capsuleattheconclusionofsurgery.Controlofpostoperative
inﬂammation also plays an important role in preventing
PCO.
Explanting an IOL. Removal of intraocular lens in uveitic
eyes is rarely necessary. Foster et al. reported that their
indications include the formation of perilental membrane,
chronic low-grade inﬂammation not responding to anti-
inﬂammatory treatment and cyclitic membrane resulting in
hypotonyandmaculopathy[85,86].Theunderlyingdiagno-
sis for uveitis included sarcoidosis, JIA, and pars planitis, in
eyeswithpredominantlyintermediateorpanuveitis,withthe
inﬂammationcenteredontheparsplanaregion.Theybelieve
that undetected subclinical inﬂammation present chroni-
cally after surgery was responsible for the postoperative14 International Journal of Inﬂammation
complications leading to IOL removal despite the necessary
precautions having been taken during the perioperative
period.
6. Conclusion and Summary
It is possible to achieve successful visual outcomes following
cataract surgery in uveitis with the modern day cataract
surgery. The predictability has improved mainly because
of a higher level of understanding of the uveitic disease
amongclinicians.Preoperativefactorsincludeproperpatient
selection and counseling and preoperative control of inﬂam-
mation. It is now well recognized that chronic inﬂammation,
even low grade, can irreversibly damage the retina and optic
nerve [6], and therefore control of inﬂammation, both pre-
and postoperatively, is vital. The use of immunosuppressive
agents other than steroids also helps control inﬂammation
and has enabled long-term use of these agents especially
as steroids sparing medication. Management of postopera-
tive complications, especially inﬂammation and glaucoma,
earlier rather than later, has also contributed to improved
outcomes. Still several questions remain unanswered, espe-
cially in the area of pediatric uveitis with cataract, which
continue to challenge the ophthalmologist to further reﬁne
the surgical technique and search for new treatment modal-
ities [56, 57]. In conclusion, management of the uveitic
cataract requires careful case selection, proper timing of
surgery, meticulous surgery and close monitoring with
appropriatehandlingofthepostoperativecomplicationsthat
may occur. These eyes can achieve good outcomes with
proper management.
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